(Z)-17-((4,5-dihydroxy-6-(hydroxymethyl)-3-((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-N-(2-(dimethylamino)ethyl)-octadec-9-enamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (Z)-17-((4,5-dihydroxy-6-(hydroxymethyl)-3-((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-N-(2-(dimethylamino)ethyl)-octadec-9-enamide
• 英文别名: (Z)-17-[4,5-dihydroxy-6-(hydroxymethyl)-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-N-[2-(dimethylamino)ethyl]octadec-9-enamide
• 化学式: C₃₄H₆₄N₂O₁₂
• 分子量: 692.888
• InChiKey: AXUOEQCHUYLEPX-PLNGDYQASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  48
• 可旋转键数：
  24
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  211
• 氢给体数：
  8
• 氢受体数：
  13

反应信息

• 作为反应物：
  描述：

  (Z)-17-((4,5-dihydroxy-6-(hydroxymethyl)-3-((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-N-(2-(dimethylamino)ethyl)-octadec-9-enamide 、 碘甲烷 以 甲醇 为溶剂， 反应 24.0h， 以85%的产率得到(Z)-2-(17-((4,5-dihydroxy-6-(hydroxymethyl)-3-((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)octadec-9-enamido)-N,N,N-trimethylethanaminium iodide
  参考文献：
  名称：

  [EN] SOPHOROLIPID ANALOG COMPOSITIONS
  [FR] COMPOSITIONS D'ANALOGUES DE SOPHOROLIPIDES

  摘要：

  一种物质组成，包含了作为抗菌剂、抗真菌剂、生物农药的Sophorolipids，可用于治疗HIV、败血症休克、癌症、哮喘、皮肤病等药物，作为杀精剂，作为抗炎药物，作为化妆品成分和单体和聚合物的构建模块以及自组装模板，以进一步进行化学改进。

  公开号：

  WO2011127101A1
• 作为产物：
  描述：

  SL-E-1 、 N,N-二甲基乙二胺 反应 12.0h， 以90%的产率得到(Z)-17-((4,5-dihydroxy-6-(hydroxymethyl)-3-((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-N-(2-(dimethylamino)ethyl)-octadec-9-enamide
  参考文献：
  名称：

  [EN] SOPHOROLIPID ANALOG COMPOSITIONS
  [FR] COMPOSITIONS D'ANALOGUES DE SOPHOROLIPIDES

  摘要：

  一种物质组成，包含了作为抗菌剂、抗真菌剂、生物农药的Sophorolipids，可用于治疗HIV、败血症休克、癌症、哮喘、皮肤病等药物，作为杀精剂，作为抗炎药物，作为化妆品成分和单体和聚合物的构建模块以及自组装模板，以进一步进行化学改进。

  公开号：

  WO2011127101A1

文献信息

• Method of treating interferon non-responders using HCV protease inhibitor
  申请人：Albrecht K. Janice

  公开号：US20070004635A1

  公开（公告）日：2007-01-04

  A method of treating, preventing or ameliorating one or more symptoms associated with hepatitis C virus (HCV) in a patient in whom either the HCV is of Genotype 1 and/or the patient was previously treated with interferon and the previous interferon therapy was ineffective to treat the one or more symptoms associated with HCV, comprising administering to such a patient an effective amount of at least one compound of formulae I-XXVI of which the following structural formula is exemplary or a pharmaceutically acceptable salt, solvate or ester thereof. Optional combined administration of said at least one compound with an interferon or pegylated interferon and/or ribaviron is also contemplated.
• SOPHOROLIPID ANALOG COMPOSITIONS
  申请人：Synthezyme, LLC

  公开号：US20140024816A1

  公开（公告）日：2014-01-23

  A composition of matter comprising sophorolipids as antimicrobial agents, antifungal agents, biopesticides, for uses as drugs to treat HIV, septic shock, cancer, asthma, dermatological conditions, as spermicidal agents, as anti-inflammatory drugs, as ingredients in cosmetics and building blocks for monomers and polymers and self-assembled templates for further chemical elaboration.
• US9051347B2
  申请人：——

  公开号：US9051347B2

  公开（公告）日：2015-06-09
• [EN] SOPHOROLIPID ANALOG COMPOSITIONS<br/>[FR] COMPOSITIONS D'ANALOGUES DE SOPHOROLIPIDES
  申请人：POLITECHNIC INST UNIV NEW YORK

  公开号：WO2011127101A1

  公开（公告）日：2011-10-13

  A composition of matter comprising sophorolipids as antimicrobial agents, antifungal agents, biopesticides, for uses as drugs to treat HIV, septic shock, cancer, asthma, dermatological conditions, as spermicidal agents, as anti-inflammatory drugs, as ingredients in cosmetics and building blocks for monomers and polymers and self-assembled templates for further chemical elaboration.

  一种物质组成，包含了作为抗菌剂、抗真菌剂、生物农药的Sophorolipids，可用于治疗HIV、败血症休克、癌症、哮喘、皮肤病等药物，作为杀精剂，作为抗炎药物，作为化妆品成分和单体和聚合物的构建模块以及自组装模板，以进一步进行化学改进。